Navigation Links
The Leukemia & Lymphoma Society Awards Major Grant to Stanford Researcher
Date:9/30/2008

LLS Specialized Center of Research Program Hits $178 Million Mark

WHITE PLAINS, N.Y., Sept. 30 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today announced it has awarded a new Marshall A. Lichtman Specialized Center of Research (SCOR) grant to Beverly Mitchell, M.D., George E. Becker Professor of Medicine at Stanford University.

Dr. Mitchell and her team will receive $1.25 million a year for five years, for a total of $6.25 million. The SCOR program is LLS's largest research grant, with total funding of $178.25 million since its inception in 2000. The title of her SCOR is: Molecular and Cellular Characterization of Myelodysplastic Syndromes.

The SCOR program brings together teams of researchers representing different disciplines in collaborative efforts to discover new approaches to treat patients with leukemia, lymphoma and myeloma. Awards go to groups that best demonstrate outstanding scientific promise facilitated by the synergy that will occur from their combined efforts.

Dr. Mitchell's team is studying stem cells in myelodysplastic syndromes (MDS), a collection of related disorders in which damaged bone marrow cells can't mature into functional blood cells. The disorders frequently progress to acute myelogenous leukemia (AML). Her team has recently identified new molecular markers than can help identify the MDS stem cells that have progressed to AML, and are working to develop therapies to target these abnormal MDS stem cells. A clinical trial of an investigational drug that targets one of the enzymes involved in the development of MDS will be initiated.

"Dr. Mitchell and her team of investigators are undertaking cutting-edge research to reach a better understanding of the root causes of MDS," said Louis DeGennaro, Ph.D., LLS's chief scientific officer. "Their work will likely lead to new therapies that target these diseases. This research team is an impressive addition to the outstanding scientists already in the SCOR program."

SCOR is one of three integrated research grant programs established by LLS. These also include the Career Development Program, which provides stipends to investigators of exceptional promise in the early stages of their careers; and the Translational Research Program, which encourages and supports outstanding research with strong promise of translating emerging biomedical knowledge into new treatments. In addition, the Therapy Acceleration Program is designed to help move potential therapies more quickly through the development pipeline.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society, headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, LLS has invested more than $600 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, LLS made 6.3 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit http://www.LLS.org or call LLS's Information Resource Center (IRC), a call center staffed by master's level social workers, nurses and health educators who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.
Andrea Greif

914-821-8958

andrea.greif@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. New leukemia signal could point way to better treatment, Stanford researchers find
2. The Leukemia & Lymphoma Society: Standing Up to Cancer for 60 Years
3. Stater Bros. Raises $200,000 for the Leukemia & Lymphoma Society
4. Methadone Kills Resistant Leukemia Cells
5. FDA Accepts Gentas NDA Amendment as Complete Response for Genasense(R) Treatment of Chronic Lymphocytic Leukemia
6. Leukemia drug could save lives of stroke patients
7. Math could help cure leukemia
8. Gene mutation improves leukemia drugs effect
9. Microenvironment a main driver of aggressive multi-lineage leukemia disease type
10. Clinical study shows biological and clinical activity in relapsed leukemia patients
11. Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology: